Results 21 to 30 of about 110,071 (192)
Progress and challenges of mRNA vaccines
Interdisciplinary Medicine, 2023 Messenger RNA (mRNA) vaccines are third‐generation nucleic acid vaccines developed after first‐generation inactivated and live‐attenuated vaccines and second‐generation subunit and viral vector vaccines, characterized by a rapid response to pathogen ...
Liangru Lin +3 more
doaj +1 more source
mRNA vaccine in cancer therapy: Current advance and future outlook
Clinical and Translational Medicine, 2023 Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer.
Youhuai Li +10 more
doaj +1 more source
Challenges Faced by States and the WHO in Efficiently Regulating the Use of mRNA Vaccines
Medical Sciences Forum, 2023 According to the World Health Organization (WHO), there is no formal regulatory guidance specifically for mRNA-based vaccines. However, the WHO provides information and regulatory considerations regarding key aspects of the manufacture and quality ...
Rabaï Bouderhem
doaj +1 more source
mRNA Vaccine Platform: mRNA Production and Delivery
Russian Journal of Bioorganic Chemistry, 2023 Vaccination is the most efficient way to prevent infectious diseases. mRNA-based vaccines is a new approach to vaccine development, which have several very useful advantages over other types of vaccines. Since mRNA encodes only the target antigen there is no potential risk of infection as in the case with attenuated or inactivated pathogens.
Litvinova, V. R. +3 more
openaire +2 more sources
Delivery Strategies for mRNA Vaccines [PDF]
Pharmaceutical Medicine, 2022 The therapeutic potential for messenger RNA (mRNA) in infectious diseases and cancer was first realized almost three decades ago, but only in 2018 did the first lipid nanoparticle-based small interfering RNA (siRNA) therapy reach the market with the United States Food and Drug Administration (FDA) approval of patisiran (Onpattro™) for hereditary ATTR ...
Sivakumar Ramachandran +2 more
openaire +2 more sources
Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”
Vaccines, 2023 Messenger RNA (mRNA) vaccines belong to a new class of medications, RNA therapeutics, including both coding and non-coding RNAs. The use of mRNA as a therapy is based on the biological role of mRNA itself, namely its translation into a functional protein.
Cristiana Perrotta +6 more
doaj +1 more source
Recent Updates on mRNA Vaccines
Vaccines, 2022 Messenger RNA has been studied by everyone, from vaccine developers to high school biology students, since the discovery of its isolation in 1961 [...]
Emily Sydow +4 more
openaire +3 more sources
Emerging trends of research on mRNA vaccines: A co-citation analysis
Human Vaccines & Immunotherapeutics, 2022 This study was designed to evaluate the emerging trends of research on mRNA vaccines. Altogether 3056 research articles related to mRNA vaccines published since 2010 were retrieved from the Web of Science database, based on which a co-citation analysis ...
Juan Chen +4 more
doaj +1 more source
Vaccines, 2021 This systematic review and meta-analysis was conducted to compare the safety and efficacy of 2019 novel coronavirus disease (COVID-19) vaccines according to vaccine platform and severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection ...
Yu-Jing Fan +2 more
doaj +1 more source
In Gratitude for mRNA Vaccines
New England Journal of Medicine, 2021 mRNA Vaccine Research and the Lasker–DeBakey Award Although the production time (11 months) of the messenger RNA vaccines against SARS-CoV-2 infection set a record, the preclinical research undergi...
openaire +2 more sources